1.860.908.4133
info@resourcesunlimitedllc.com
1905 Audubon Ct.
Spokane, WA 99224
Menu

Tag: etbi

08-27-2018 – ETBI – EastGate Biotech Signs Definitive Investment and European Licensing Agreement With Nico Innovagroup S.r.l. for Liquid Insulin Mouth Rinse Solution

August 27, 2018
| No Comments
| Categories: Uncategorized

Non-Dilutive Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 27, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, signed a definitive agreement effective August 10th, 2018 with Nico Innovagroup S.r.l. with its principal headquarters in Brescia, Italy. The definitive agreement encompasses the license of the company's liquid insulin mouth rinse solution for a period of 15 years in the European market in exchange for milestone payments and a...

Read More

07-24-2018 – ETBI – EastGate Biotech Provides Update on Investment From Genluiching Mining Corporation

July 25, 2018
| No Comments
| Categories: Uncategorized

EastGate to Receive the First Non-dilutive Investment Tranch from the Total Funding up to $5 million USD as per the Terms of the Definitive Agreement WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / July 24, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced that it is to receive the first tranch of the investment from Genluiching Mining Corporation as per the definitive agreement signed in April. As per the previously announced executed Definitive Agreement, Genluiching Mining will invest...

Read More

06-21-2018 – ETBI – EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for Its Liquid Insulin Mouth Rinse Solution

July 16, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 21, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a Memorandum of Understanding (MOU) with Mystic Pharmaceuticals Limited (www.mysticpharma.info) of Bangladesh. The scope of the MOU is to focus on the manufacturing of the company's liquid insulin mouth rinse solution for specific markets. Presently, EastGate is developing its insulin mouth rinse in the Philippines, Pakistan, and Europe through its JV with Nico Innovapharma. The terms of...

Read More

06-19-2018 – ETBI – EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market

July 16, 2018
| No Comments
| Categories: Uncategorized

Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a binding Memorandum of Understanding (MOU) with Nico Innovapharma (www.nicoinnovagroup.com) (www.nilamedica.com), an innovative start up under incorporation, with its principal headquarters in Brescia, Italy. The scope of the MOU is for the licensing of the company's liquid insulin mouth rinse solution. The terms of the MOU detail...

Read More

03-05-2018 – ETBI – EastGate Biotech Announces Licensing/Distribution MOU With BuPharco for the Insulin Mouth Rinse in the Philippines for Type 2 Diabetes Patients

March 11, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 5, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA...

Read More

03-01-2018 – ETBI – Eastgate Biotech Provides Corporate Update

March 11, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 1, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced today its corporate update. EastGate Biotech is pleased to provide its shareholders with the following corporate update: The Company's strategic moves over the past year to improve its underlying operations were part of a corporate vision to be a "disrupter" in the drug delivery sector targeting unmet medical needs. As a company, we collectively agreed that drug development...

Read More